Log in

Novus Therapeutics Stock Forecast, Price & News

-0.01 (-1.03 %)
(As of 09/28/2020 12:00 AM ET)
Today's Range
Now: $0.96
50-Day Range
MA: $0.56
52-Week Range
Now: $0.96
Volume495,107 shs
Average Volume1.72 million shs
Market Capitalization$18.63 million
P/E RatioN/A
Dividend YieldN/A
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Read More
Novus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NVUS



Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share


Net Income$-16,010,000.00


Market Cap$18.63 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
-0.01 (-1.03 %)
(As of 09/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

How has Novus Therapeutics' stock price been impacted by COVID-19?

Novus Therapeutics' stock was trading at $0.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVUS stock has increased by 128.8% and is now trading at $0.9611.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Novus Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novus Therapeutics

When is Novus Therapeutics' next earnings date?

Novus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Novus Therapeutics

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics Inc (NASDAQ:NVUS) posted its earnings results on Friday, August, 14th. The biopharmaceutical company reported ($0.15) EPS for the quarter.
View Novus Therapeutics' earnings history

What price target have analysts set for NVUS?

3 analysts have issued 1-year price objectives for Novus Therapeutics' stock. Their forecasts range from $0.60 to $3.25. On average, they expect Novus Therapeutics' share price to reach $1.95 in the next year. This suggests a possible upside of 102.9% from the stock's current price.
View analysts' price targets for Novus Therapeutics

Are investors shorting Novus Therapeutics?

Novus Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 118,400 shares, a decrease of 44.0% from the August 31st total of 211,400 shares. Based on an average trading volume of 3,700,000 shares, the days-to-cover ratio is currently 0.0 days.
View Novus Therapeutics' Short Interest

Who are some of Novus Therapeutics' key competitors?

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Geron (GERN), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Verastem (VSTM), vTv Therapeutics (VTVT) and Corbus Pharmaceuticals (CRBP).

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the following people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 49)
  • Dr. Catherine C. Turkel, Pres (Age 58)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 54)

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $0.96.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $18.63 million. The biopharmaceutical company earns $-16,010,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is novustherapeutics.com.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.